-
1 month ago | 
nature.com | Aqeeb ur Rehman |Moazzam Shahzad |Faiz Anwer |Joseph McGuirk |Mohamad Mohty |Nausheen Ahmed | +1 more
AbstractMeasurable residual disease (MRD) testing is emerging as a crucial prognostic and treatment-guiding tool in multiple myeloma (MM). Despite its potential, routine clinical adoption remains inconsistent. This study aimed to explore oncologists’ perspectives on MRD testing and identify barriers and facilitators to its clinical integration. A cross-sectional, modified Delphi survey was conducted among hematologists and oncologists globally, and 115 responses were received.
-
Jan 31, 2025 | 
cancernetwork.com | Al-Ola Abdallah |Muhammad Umair Mushtaq |Jeries Kort |Zahra Mahmoudjafari
January 31, 2025By Panelists discuss how expanding CAR T therapy into earlier lines of multiple myeloma treatment requires careful evaluation of clinical trial data, infrastructure readiness, patient selection criteria, and manufacturing capacity while balancing the therapy’s potential benefits against established treatment approaches.
-
Jan 31, 2025 | 
cancernetwork.com | Al-Ola Abdallah |Muhammad Umair Mushtaq |Jeries Kort |Zahra Mahmoudjafari
January 31, 2025By Panelists discuss how successful comanagement of CAR T-cell therapy cases requires close coordination between academic centers and community practices, with structured protocols for monitoring, communication, and patient handoffs, while addressing challenges in referral timing, resource allocation, and long-term follow-up care.
-
Jan 24, 2025 | 
cancernetwork.com | Al-Ola Abdallah |Muhammad Umair Mushtaq |Jeries Kort |Zahra Mahmoudjafari
January 24, 2025By Panelists discuss how CAR T-cell therapy, a groundbreaking immunotherapy treatment, works by extracting a patient’s T cells, genetically modifying them to target cancer cells, and reinfusing them back into the patient’s body through a process that involves close monitoring and specialized careVideo content above is prompted by the following:Could you explain how CAR T-cell therapy works and describe the treatment process at University of Kansas Medical Center?
-
Jan 24, 2025 | 
cancernetwork.com | Al-Ola Abdallah |Muhammad Umair Mushtaq |Jeries Kort |Zahra Mahmoudjafari
January 24, 2025By Panelists discuss how bridging therapy during the CAR T manufacturing waiting period requires careful patient-specific decisions about whether to use chemotherapy, targeted agents, or observation alone, based on disease aggressiveness, patient condition, and expected manufacturing timeframes. Video content above is prompted by the following:Can you explain your institution’s approach to bridging therapy for patients awaiting CAR T-cell manufacturing and infusion?
-
Jan 20, 2025 | 
cancernetwork.com | Al-Ola Abdallah |Muhammad Umair Mushtaq |Jeries Kort |Zahra Mahmoudjafari
January 20, 2025By Panelists discuss how the chimeric antigen receptor T-cell referral pathway progresses from initial community physician contact through patient evaluation and final selection, highlighting the key steps and considerations in the institutional workflow process.
-
Jan 10, 2025 | 
cancernetwork.com | Al-Ola Abdallah |Muhammad Umair Mushtaq |Jeries Kort |Zahra Mahmoudjafari
January 10, 2025By Panelists discuss how patient selection criteria for second-line chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma encompass both clinical eligibility guidelines and practical considerations, including geographical and financial factors.
-
Jan 6, 2025 | 
cancernetwork.com | Al-Ola Abdallah |Muhammad Umair Mushtaq |Zahra Mahmoudjafari |Jeries Kort
January 3, 2025By Panelists discuss how institutional challenges around chimeric antigen receptor T-cell therapy slot availability and waiting list management influence treatment sequencing decisions and affect subsequent therapy choices in earlier treatment lines for multiple myeloma.
-
Aug 4, 2023 | 
cancernetwork.com | Al-Ola Abdallah |Leyla O. Shune |Nausheen Ahmed |Jordan Snyder
Transcript:Al-Ola Abdallah, MD: Jordan, this is a case we’re commonly seeing that’s unfortunately common. We have to talk about the issue of infection rate, which is very high with [the use of] bispecifics. We’re going to use them more, and we’re not talking about just as a single agent. This is a single agent, by the way. But in combination therapy we’re going to see more than that. With daratumumab there’s an increased risk for infection.
-
Jul 28, 2023 | 
cancernetwork.com | Al-Ola Abdallah |Leyla O. Shune |Nausheen Ahmed |Jordan Snyder
Transcript:Al-Ola Abdallah, MD: Nausheen, many BCMA BiTES [bispecific T-cell engagers] are coming out, and there are other targeted therapies that Dr Leyla [Shune] told us about. Can you talk about some of these drugs, like talquetamab and cevostamab? Nausheen Ahmed, MD: These are promising therapies coming out. Once we start using these BCMA therapies and seeing resistance to BCMA-directed therapies, then these are other targets.
